Connect with us

Media & Technology

TPT Global Tech, Inc. (OTCMKTS: TPTW) Parabolic Runner After Tech Pioneer Inks Major Deal with Skybridge West Africa (SWA) to Build Over 100,000 Homes

Published

on

TPT Global Tech, Inc. (OTCMKTS: TPTW) is skyrocketing up the charts after the Company entered into a strategic technology agreement with Skybridge West Africa (SWA) www.skybridgewa.com, to participate in the development of 20 SMART Villages $5B Green Housing and Educational Learning Project in Ghana West Africa. TPTW’s participation could eventually be worth upwards of $3.5 billion in new contracts and management fees according to the Company. SWA has been awarded a $5B community development approval from the Ghanaian Ministry of Works and Housing to develop and build over 100,000 newly constructed homes utilizing the latest green technology over the next 5 years. The Smart Village infrastructure will consist of new home design and construction, new transportation capabilities, renewable energy, waste management technologies, installation of high-speed fiber-optic, 5G wireless cell towers, last-mile wireless technology, and ultra-performance cement technology. Skybridge will also develop the education system and programs for the new Smart Village. 

This represents a massive deal for TPTW which will provide the Ghanaian Smart Village with its proprietary suite of technology platforms including its ‘QuikLABS’ and ‘QuikPASS’ medical testing and verification systems, design and build the 5G wireless cell towers, fiber infrastructure and renewable energy technology for electricity and water. The company will also be providing ultra-performance concrete technology for roads, plumbing, sewer pipes, toilets, bathtubs, sinks, tiles and decorative fixtures for the housing community and medical clinics throughout the Smart Village. The estimated contract award portion to TPT Global Tech for its technology contributions and infrastructure build is estimated to be $3.5B USD of the total $5B USD Smart Village budget over the next 5 years. 

TPT Global Tech, Inc. (OTCMKTS: TPTW) Is a technology-based company with divisions providing telecommunications, medical technology and product distribution, media content for domestic and international syndication as well. The Company’s operating subsidiaries are SpeedConnect, TPT Med Tech, Blue Collar Productions, ViewMe Live, BridgeInternet, and TPT Mobil. TPTW is led by CEO Stephen J. Thomas III, an award-winning tech entrepreneur who has worked in high level executive management positions for over 20 years. Back in 2002, as CEO of Trans Pacific Telecom, Inc., Mr. Thomas was featured on CBS market watch for winning “Product of the Year Award” at the Internet Telephone Conference and Expo for VIVOware, a feature-rich billing and customer care software. 

Microcapdaily has reproted on TPTW many times in the past writing in our first article on the Company on February, 20, 2020 stating TPT Global Tech, Inc. (OTCMKTS: TPTW) has made a fast move up in recent days since reversing off $0.00012 lows. The stock has quickly attracted a large growing shareholder base that continues to bid it higher. TPT Global Tech bills itself as a Technology/Telecommunications Media Content Hub for Domestic and International syndication and also provides Technology solutions to businesses domestically and worldwide. TPT Global offers Software as a Service (SaaS), Technology Platform as a Service (PAAS), Cloud-based Unified Communication as a Service (UCaaS) and carrier-grade performance and support for businesses over its private IP MPLS fiber and wireless network in the United States. TPT’s cloud-based UCaaS services allow businesses of any size to enjoy all the latest voice, data, media and collaboration features in today’s global technology markets. TPT’s also operates as a Master Distributor for Nationwide Mobile Virtual Network Operators (MVNO) and Independent Sales Organization (ISO) as a Master Distributor for Pre-Paid Cellphone services, Mobile phones Cellphone Accessories and Global Roaming Cellphones. 

https://twitter.com/S_AnglinIV/status/1430538491847487493

To Find out the inside Scoop on TPTW Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

TPTW

As part of this total $5 Billion project, SWA envisions housing that not only provides homes but also communities that recognize the requirements for affordable housing. To that end, SWA proposes to include the following elements as major components of its livable communities: Plan SMART Communities, Entrepreneurship Incubator, Construct Relevant Infrastructure, Schools, teacher-driven – (universal availability of work-class content), cloud-based mastery learning educational content, one-to-one device ratio, medical clinics, renewable energy, water/wastewater management, agriculture/Micro-Ag., integrated technology (community broadband), SMART transportation options, infrastructure, entrepreneurial jobs creation estimated at 25k+ over 10 years (based on World Bank estimate of job creation ratios), construction of off-site prefabricated construction factory and integration of technology into the design and construction. 

“We are pleased and excited to join hands with Skybridge West Africa and feel fortunate that TPT Global Tech has been selected as the lead technology partner. TPT is uniquely positioned through its various subsidiaries, technology platforms and years of experience working in Africa and emerging markets to assist Skybridge with its Smart Village objectives in Ghana. This planned project will help position the company for future international project consideration and continue to position the company for its up listing to a major exchange,” said TPT Global Tech’s Chairman & CEO, Stephen J. Thomas III. 

 

For More on TPTW Subscribe Right Now!

TPTW is skyrocketing up the charts after the Company entered into a strategic technology agreement with Skybridge West Africa (SWA) www.skybridgewa.com, to participate in the development of 20 SMART Villages $5B Green Housing and Educational Learning Project in Ghana West Africa. TPTW’s participation could eventually be worth upwards of $3.5 billion in new contracts and management fees according to the Company. SWA has been awarded a $5B community development approval from the Ghanaian Ministry of Works and Housing to develop and build over 100,000 newly constructed homes utilizing the latest green technology over the next 5 years. The Smart Village infrastructure will consist of new home design and construction, new transportation capabilities, renewable energy, waste management technologies, installation of high-speed fiber-optic, 5G wireless cell towers, last-mile wireless technology, and ultra-performance cement technology. Skybridge will also develop the education system and programs for the new Smart Village.  This represents a massive deal for TPTW which will provide the Ghanaian Smart Village with its proprietary suite of technology platforms including its ‘QuikLABS’ and ‘QuikPASS’ medical testing and verification systems, design and build the 5G wireless cell towers, fiber infrastructure and renewable energy technology for electricity and water. The company will also be providing ultra-performance concrete technology for roads, plumbing, sewer pipes, toilets, bathtubs, sinks, tiles and decorative fixtures for the housing community and medical clinics throughout the Smart Village. The estimated contract award portion to TPT Global Tech for its technology contributions and infrastructure build is estimated to be $3.5B USD of the total $5B USD Smart Village budget over the next 5 years.  We will be updating on TPTW when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with TPTW.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in TPTW either long or short and we have not been compensated for this article.

Featured

Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI

Published

on

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com.

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.

Revolutionizing User Experience and Driving Stock Surge

With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.

To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Evaluating Financial Performance

While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.

Investment Outlook and Future Prospects

Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.

About MightyDeals.com

Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.

About Onfolio Holdings Inc.

Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.

Conclusion

Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.

We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by James from Pixabay

Continue Reading

Featured

Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment

Published

on

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news.

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.

The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.

To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.

Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.

We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gino Crescoli from Pixabay

Continue Reading

Featured

Amgen (NASDAQ: AMGN) and TScan Therapeutics, Inc. (NASDAQ: TCRX) Secure Partnership

Published

on

Amgen (NASDAQ: AMGN) and TScan Therapeutics, Inc. (NASDAQ: TCRX) today announced a multi-year collaboration that will use TScan's proprietary target discovery platform.

TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million.

Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities

Amgen (NASDAQ: AMGN) and TScan Therapeutics, Inc. (NASDAQ: TCRX) today announced a multi-year collaboration that will use TScan’s proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn’s disease.

All things considered, this is among one of the largest deals you’ll see for a micro-cap biopharma company. As many of you know, companies in this sector of this size and scale are typically not profitable – mainly focusing on R&D until their drug or technology is fully approved/commercially viable. 

The critical thing to note with this deal between TScan and Amgen is that the cash milestones ensure a cash runway for TCRX, potentially even until they become commercially viable and profitable. 

Here’s a breakdown of the press release in layman’s terms, so anyone without background or knowledge in this space can better understand: 

Amgen and TScan Therapeutics are teaming up to find new treatments for Crohn’s disease, a chronic condition that causes inflammation in the gut. TScan has a unique platform called TargetScan that can identify the proteins recognized by the immune system in people with the disease. Amgen will use this information to create new drugs to treat Crohn’s disease.

As part of the deal, TScan will get an upfront payment of $30 million from Amgen and could earn more than $500 million if the collaboration is successful. Amgen will have the rights to develop and sell any new drugs from this partnership.

To Discover the Inside Scoop on TCRX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Both companies will be responsible for their research costs, and Amgen can expand the collaboration to include another condition called ulcerative colitis. This partnership could lead to new and better treatments for people with Crohn’s disease, who currently have limited options for managing their symptoms.

Here are a couple of blurbs from the management team

“Anti-inflammatory drugs have traditionally been the standard of care for patients suffering from inflammatory bowel disease, but often lack efficacy and durability,” said Raymond Deshaies, Ph.D., senior vice president of Global Research at Amgen. “TScan’s platform provides a best-in-class approach to identify non-conventional drug targets to enable the development of potential first-in-class therapeutics to address unmet medical needs.”

“We’re excited to apply our target discovery platform to the autoimmunity space,” said Gavin MacBeath, Ph.D., acting chief executive officer and chief scientific and operating officer at TScan. “Our TargetScan platform, which we have now extended to identify MHC class II targets of CD4+ T cells, is well-suited for the discovery of antigens targeted by the immune system in inflammatory bowel disease. We look forward to developing the value of our platform both in this partnership with Amgen and in other autoimmune diseases.”

What’s retail saying?

As per usual, with gains of around 135%, you can probably guess that retail is all over it. Investors practically all over the internet keep their eye on the stock for potential entry points utilizing various day trading techniques. 

Interestingly, some traders are surprised it managed to trade such massive volumes early intraday. If you look at their chart from the prior months, the average volume was relatively minuscule – sometimes trading as low as 5K shares a day.  Compared to the ~27M shares traded at the time of writing, that’s a massive shift.

We will update you on TCRX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening with TCRX.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gerd Altmann from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.